Glenmark enrols first patient for phase II trial of GBR 500
The company out licensed Vatelizumab (GBR 500) to Sanofi for all indications in 2011
Author
US FDA votes against Novartis’ LBH589 compound
(ODAC) did not recommend the investigational compound LBH589, a pan-deacetylase inhibitor, for patients with previously treated…
Study confirms positive safety profile and effectiveness of Pradaxa in atrial fibrillation patients
The FDA Medicare analysis is based on patient data from elderly patients enrolled in Medicare
Clinical Research
What does the next 20 years hold for clinical research in India? Express Pharma presents some perspectives and sugestions for…
Clinical research in India: Where do we go from here?
A policy promoting clinical research and innovation needs to be supported by action at various levels opines Suneela Thatte,…
Bring research back on the agenda
The country has a responsibility towards the health of its citizens that translates to creating an enabling environment, advocates…
CT regulation in India: Science or social justice?
Mark Barnes, JD, LLM Faculty Co-Director, Multi-Regional Clinical Trials Center at Harvard (Harvard MRCT), Lecturer, Harvard Law…
MSF urges India to stand strong against attack on affordable medicines
Many governments and treatment providers rely on affordable quality generic medicines from India to treat life-threatening…
Celebrating 20 Years
1994-2014 Express Pharma Pulse to Express Pharma
As we mark Express Pharma’s 20th anniversary, experts retrospect on some of the…
India on the brink of an opportunity
On Express Pharma’s 20th Anniversary, Ranjana Smetacek, Director General, Organisation of Pharmaceutical Producers of India (OPPI)…